Evelo Biosciences to Present at Virtual BMO 2020 Prescriptions for Success Healthcare Conference

Rhea-AI Summary

Evelo Biosciences, a clinical-stage biotechnology company, announced participation in the BMO 2020 Prescriptions for Success Healthcare Conference on June 23 at 11:00 a.m. ET. This event will be available via a live audio webcast on their website, with a replay accessible for 30 days post-event. Evelo focuses on developing orally delivered biologics that target immune, metabolic, and neurological systems, with product candidates for inflammatory diseases and cancer. Their therapies aim to provide effective and affordable treatment options.

CAMBRIDGE, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that management will participate in a fireside chat at the virtual BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23^rd at 11:00 a.m. ET.

A live audio webcast of the presentation will be available on the Investors section of the Evelo website at http://ir.evelobio.com/news-events. A replay of the webcast will be available for approximately 30 days following the presentation.

About Evelo Biosciences
Evelo Biosciences, Inc. is a clinical stage biotechnology company developing oral biologics that act on SINTAX with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic and neurological systems. The company’s first product candidates are single strains of microbes selected for defined pharmacological properties. Evelo’s therapies have the potential to be effective, safe and affordable medicines to improve the lives of people with chronic diseases and cancer.

Evelo currently has four product candidates: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases, and EDP1503 for the treatment of cancer. Evelo is also advancing additional oral biologics through preclinical development in other disease areas.

For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn.

Contact
Evelo Biosciences
Jessica Cotrone, 978-760-5622
jcotrone@evelobio.com

FAQ

What is Evelo Biosciences' participation in the BMO 2020 Healthcare Conference?

Evelo Biosciences will participate in a fireside chat at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23 at 11:00 a.m. ET.

How can I watch the Evelo Biosciences presentation at the conference?

The presentation will be available via a live audio webcast on the Investors section of the Evelo website, with a replay for about 30 days after.

What are the key product candidates of Evelo Biosciences?

Evelo's key product candidates include EDP1815, EDP1867, EDP2939 for inflammatory diseases, and EDP1503 for cancer treatment.

What is the focus of Evelo Biosciences' research?

Evelo focuses on developing orally delivered biologics that act on SINTAX for systemic therapeutic effects in chronic diseases and cancer.

When was the press release regarding Evelo Biosciences' conference participation issued?

The press release was issued on June 16, 2020.